The FDA granted priority-review designation to Pfizer and Bristol-Myers Squibb's Eliquis, or apixaban, and is expected to decide on the anti-clotting drug by March 28, 2012. The drugmakers aim to launch Eliquis for stroke prevention among patients with atrial fibrillation. If approved, Eliquis will be the third such treatment, after Bayer and Johnson & Johnson's Xarelto and Boehringer Ingelheim's Pradaxa.

Related Summaries